Trial
NCT01433978
A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Eisai Inc.
Collaborators
—
Condition
Idiopathic Thrombocytopenic Purpura
Intervention
Eltrombopag
Why stopped
Study was terminated early due to significant enrollment challenges.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-06